



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

To, November 10, 2017
The Listing Department,
BSE Ltd.

Sub: Outcome of Board Meeting held on November 10, 2017.

We wish to inform you that the Board Directors of the Company, at their just concluded meeting have inter alia, approved the unaudited financial results for the half year ended September 30, 2017 as recommended by the Audit Committee and reviewed by Statutory Auditors of the Company.

Please find enclosed the unaudited financial results for the half year ended September 30, 2017 along with the limited review report issued by the Statutory Auditor of the Company.

The meeting commenced at 2.30 P.M. and concluded at 5.40 P.M.

This for your information and dissemination to the public.

For VANTA BIOSCIENCE LIMITED
Scrip Code: 540729 | Scrip ID: VANTABIO

DOPESH RAJA MULAKALA
MANAGING DIRECTOR
DIN: 01176660





MATHESH & RAMANA
CHARTERED ACCOUNTANTS

Review Report to the Board of Directors of VANTA BIOSCIENCE LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/s Vanta Bioscience Limited for the period of six months ended on 30th September, 2017. This statement is the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements Issued by the Institute of Chartered Accountants of India. This standard required that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 10/11/2017



For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

B. V. RAMANA REDDY
M. No. 028967 Partner



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : U74999TG2016PLC109280

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR

ENDED ON 30TH SEPTEMBER, 2017

(Rs. In Lakhs)

PARTICULARS	Six months ended on 30.09.2017 (Unaudited)	Preceding six months ended on 31.03.2017 (Audited)	Corresponding Six months ended in the previous year on 30.09.2016	Previous year ended on 31.03.2017 (Audited)
I INCOME:				
Revenue from Operations	49.35	-	-	-
Total Revenue	49.35	-	-	-
II EXPENDITURE:				
Employee Benefits Expenses	11.80	-	-	-
Finance Costs	3.84	-	-	-
Depreciation	16.38	-	-	-
Other Expenses	11.04	-	-	-
Total Expenses	43.06	-	-	-
Profit(Loss) before exceptional and extraordinary Items and Tax	6.29	-	-	-
Exceptional Item	-	-	-	-
Profit(Loss) before extraordinary Items and Tax	6.29	-	-	-
Extraordinary Items	-	-	-	-
Profit(Loss) before tax	6.29	-	-	-
Tax Expenses	-	-	-	-
Profit(Loss) for the period	6.29	-	-	-
Earning per equity share : (In Rupees)				
Basic	0.15	-	-	-
Diluted	0.15	-	-	-

For VANTA BIOSCIENCE LIMITED

DORESH RAJA MULAKALA

MANAGING DIRECTOR

DIN: 01176660

Secunderabad, 10th November, 2017



For VANTA BIOSCIENCE LIMITED

VENKAT RAO SADHANALA

CHIEF FINANCIAL OFFICER

Research Center :

K2-B, 11th Cross Street, SIPCOT Industrial Complex,
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
Tel : 044 6790 1600



Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
 Rasoolpura, Secunderabad - 500 003, INDIA.
 Tel : +91 40 6657 5454, 2790 3226
 Fax : +91 40 2790 8708
 Website : www.vantabio.com
 Email : info@vantabio.com
 CIN No. : U74999TG2016PLC109280

**UNAUDITED STATEMENT OF ASSETS AND LIABILITIES FOR THE HALF YEAR
 ENDED AS AT 30TH SEPTEMBER, 2017 (Rs. In Lakhs)**

	As at the Current half year ended on 30.09.2017 (Unaudited)	As at the previous year ended on 31.03.2017 (Audited)
I EQUITY & LIABILITIES		
1. Shareholders' Funds:		
a. Share Capital	421.60	364.60
b. Reserves & Surplus	484.69	250.40
	906.29	615.00
2. Non-Current Liabilities		
a. Long Term Borrowings	805.79	750.00
c. Other Long Term Liabilities	0.54	0.54
	806.33	750.54
3. Current Liabilities		
b. Trade Payables	4.73	-
c. Other Current Liabilities	124.35	9.05
	129.08	9.05
	1,841.70	1,374.59
II ASSETS		
Non-Current Assets		
1 (a) Fixed Assets :		
(i) Tangible Assets	1,300.91	1,294.61
(i) Intangible Assets	341.52	-
(b) Long-Term Loans and Advances	35.04	27.48
	1,677.47	1,322.09
2. Current Assets		
a. Inventories	22.19	-
b. Trade Receivables	16.80	-
c. Cash and Cash Equivalents	42.43	44.45
d. Short-Term Loans and Advances	51.87	-
e. Other Current Assets	5.85	2.32
	139.13	46.77
3. Miscellaneous Expenditure : (To the extent not written off or adjusted)	25.10	5.74
	1,841.70	1,374.59

For VANTA BIOSCIENCE LIMITED

M. Dopesha Raja

DOPESH RAJA MULAKALA
 MANAGING DIRECTOR
 DIN: 01176660

Secunderabad, 10th November, 2017



For VANTA BIOSCIENCE LIMITED

S. Venkata Rao

VENKAT RAO SADHANALA
 CHIEF FINANCIAL OFFICER

Research Center :

K2-B, 11th Cross Street, SIPCOT Industrial Complex,
 Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.
 Tel : 044 6790 1600

Notes:

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their Meeting held on Friday, 10th November, 2017.
2. As required under Regulation 33 of the SEBI (LODR) Regulation, 2015, the Statutory Auditors of the Company have issued Limited Review Report on the aforesaid unaudited financial results for the half year ended 30th September, 2017 which was also taken on record by the Audit Committee and Board at their meeting held on Friday, 10th November, 2017. The Report does not have any impact on the aforesaid financial results which needs any explanation by the Board.
3. The Company has purchased the assets of Vanta Bioscience Division in March, 2017 and there were no commercial operations during the previous financial year 2016-2017. Hence, no Profit & Loss Statement is drawn for the said financial year ended on 31st March, 2017. Based on the above the previous year's financial figures are nil.
4. The Company had gone for IPO of 15.12 Lakhs of Equity Share of face value of Rs. 10/- at an issue price of Rs. 50/- per share, which was successfully subscribed. The said shares were allotted done on 05th October, 2017. The company's shares were listed on BSE SME Platform w.e.f 06th October, 2017. The total proceeds received from IPO is Rs. 756.00 lakhs.
5. As per MCA Notification dated 16th February, 2015, the Companies whose Shares are listed with BSE SME Platform as referred to in Chapter XB of SEBI (issue of Capital and Disclosure Requirements) Regulations, 2009, are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. Earnings per Share: Earnings per share have been calculated on the weighted average of the share capital outstanding during the year. Half yearly is not annualized.
7. Depreciation has been provided as per the Companies Act, 2013. The depreciation in the financials captured based on the date of commencement of business operations.
8. Statement of Assets and Liabilities as on 30th September, 2017 is enclosed herewith.

Dr. Deepak Bajaj



[Signature]